European Urology

Journal

Publication Venue For

  • Reply to Yongbao Wei, Haijian Huang, and Liefu Ye's Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469–82..  83:e16-e17. 2023
  • The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors.  82:469-482. 2022
  • The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours.  82:458-468. 2022
  • Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer[Formula presented].  79:364-371. 2021
  • Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial [Figure presented].  74:66-73. 2018
  • Zero-fragment Nephrolithotomy: A Multi-center Evaluation of Robotic Pyelolithotomy and Nephrolithotomy for Treating Renal Stones.  72:1014-1021. 2017
  • Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis.  70:372-381. 2016
  • The Neoadjuvant Paradigm for Development of Systemic Therapy and Precision Medicine for Bladder Cancer.  69:863-865. 2016
  • A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.  69:428-435. 2016
  • Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.  69:157-165. 2016
  • Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.  68:555-567. 2015
  • A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.  67:778-786. 2015
  • Do the sites of metastases provide additional information regarding prognosis and biology in renal cell carcinoma?.  65:585-586. 2014
  • Words of wisdom. Re: Prognostic influence of the third Gleason grade in prostatectomy specimens..  65:498-499. 2014
  • A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.  66:550-560. 2014
  • ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.  66:77-84. 2014
  • Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.  64:713-719. 2013
  • Prostate cancer genomics: Progress and promise.  64:577-578. 2013
  • Laparoendoscopic single-site partial nephrectomy: A multi-institutional outcome analysis.  64:314-322. 2013
  • Metabolism of kidney cancer: From the lab to clinical practice.  63:244-251. 2013
  • A contemporary update on pathology reporting for prostate cancer: Biopsy and radical prostatectomy specimens.  62:20-39. 2012
  • Laparoendoscopic single-site surgery in urology: Worldwide multi-institutional analysis of 1076 cases.  60:998-1005. 2011
  • Letter to the editor.  58. 2010
  • The Epstein Criteria Predict for Organ-Confined But Not Insignificant Disease and a High Likelihood of Cure at Radical Prostatectomy.  58:90-95. 2010
  • Robotic-Assisted Laparoscopic Intracorporeal Urinary Diversion.  57:1013-1021. 2010
  • Prospective Randomized Controlled Trial of Robotic versus Open Radical Cystectomy for Bladder Cancer: Perioperative and Pathologic Results.  57:196-201. 2010
  • Reply from Authors re: Oliver W. Hakenberg. Moving Towards Evidence-based Surgery. Eur Urol 2010;57:202-3.  57:203-204. 2010
  • Urogenital Pain - Time to Accept a New Approach to Phenotyping and, as a Consequence, Management.  53:33-36. 2008
  • 2007 Guideline for the Management of Ureteral Calculi.  52:1610-1631. 2007
  • Evaluation of biomarker modulation by fenretinide in prostate cancer patients.  35:429-438. 1999
  • A comparison of perspectives on prostate cancer: Analysis of utility assessments of patients and physicians.  32:86-88. 1997
  • Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation.  29:425-433. 1996
  • Biomarker expression in prostatic intraepithelial neoplasia.  30:153-166. 1996
  • Molecular events in the early phases of prostate carcinogenesis.  30:167-176. 1996

    • International Standard Serial Number (issn)

  • 0302-2838

    • Electronic International Standard Serial Number (eissn)

  • 1873-7560